search
Back to results

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
budesonide/formoterol
budesonide
formoterol
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, Symbicort, budesonide/formoterol, budesonide, formoterol

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • At least 12 years of age
  • Diagnosis of asthma
  • Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol

Exclusion Criteria:

  • Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
  • Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Active Comparator

    Active Comparator

    Arm Label

    1

    2

    3

    Arm Description

    budesonide

    formoterol

    Outcomes

    Primary Outcome Measures

    12 hour serial FEV1 measurements and withdrawals due to asthma exacerbation

    Secondary Outcome Measures

    Lung function, asthma symptoms, use of rescue medication, adverse events and other safety assessments

    Full Information

    First Posted
    April 1, 2008
    Last Updated
    January 21, 2011
    Sponsor
    AstraZeneca
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00652002
    Brief Title
    Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
    Official Title
    A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2002 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    January 2004 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    AstraZeneca

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Asthma
    Keywords
    Asthma, Symbicort, budesonide/formoterol, budesonide, formoterol

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    450 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Title
    2
    Arm Type
    Active Comparator
    Arm Description
    budesonide
    Arm Title
    3
    Arm Type
    Active Comparator
    Arm Description
    formoterol
    Intervention Type
    Drug
    Intervention Name(s)
    budesonide/formoterol
    Other Intervention Name(s)
    Symbicort
    Intervention Type
    Drug
    Intervention Name(s)
    budesonide
    Intervention Type
    Drug
    Intervention Name(s)
    formoterol
    Primary Outcome Measure Information:
    Title
    12 hour serial FEV1 measurements and withdrawals due to asthma exacerbation
    Time Frame
    FEV1: before start of tretment and at 2 and 12 weeks after start of treatment. Withdrawals: throughout the treatment period
    Secondary Outcome Measure Information:
    Title
    Lung function, asthma symptoms, use of rescue medication, adverse events and other safety assessments
    Time Frame
    Throughout the treatment period

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    12 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: At least 12 years of age Diagnosis of asthma Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol Exclusion Criteria: Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Catherine Bonuccelli
    Organizational Affiliation
    AstraZeneca
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    27039236
    Citation
    Tashkin DP, Moore GE, Trudo F, DePietro M, Chipps BE. Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):705-12. doi: 10.1016/j.jaip.2016.02.014. Epub 2016 Mar 30.
    Results Reference
    derived
    PubMed Identifier
    24524222
    Citation
    Tashkin DP, Chipps BE, Trudo F, Zangrilli JG. Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. J Asthma. 2014 Aug;51(6):603-9. doi: 10.3109/02770903.2014.895012. Epub 2014 Mar 19.
    Results Reference
    derived
    PubMed Identifier
    22329608
    Citation
    Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 1;12(1):9-14. doi: 10.2165/11630600-000000000-00000. Erratum In: Drugs R D. 2012 Mar 1;12(1):15.
    Results Reference
    derived

    Learn more about this trial

    Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

    We'll reach out to this number within 24 hrs